David E Schrodinger Equity ... Net Worth

The estimated Net Worth of David E Schrodinger Equity ... is at least $727 Million dollars as of 19 July 2021. David Equity owns over 63,061 units of Schrodinger stock worth over $125,600,604 and over the last 5 years David sold SDGR stock worth over $600,925,326.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Equity SDGR stock SEC Form 4 insiders trading

David has made over 36 trades of the Schrodinger stock since 2020, according to the Form 4 filled with the SEC. Most recently David sold 63,061 units of SDGR stock worth $4,292,562 on 19 July 2021.

The largest trade David's ever made was selling 919,793 units of Schrodinger stock on 7 October 2020 worth over $50,680,594. On average, David trades about 239,807 units every 8 days since 2020. As of 19 July 2021 David still owns at least 6,103,042 units of Schrodinger stock.

You can see the complete history of David Equity stock trades at the bottom of the page.

Insiders trading at Schrodinger

Over the last 5 years, insiders at Schrodinger have traded over $1,009,056,149 worth of Schrodinger stock and bought 838,235 units worth $14,249,995 . The most active insiders traders include & Melinda Gates Foundation ..., David E Schrodinger Equity ..., and Michael Lynton. On average, Schrodinger executives and independent directors trade stock every 10 days with the average trade being worth of $2,459,207. The most recent stock trade was executed by Kenneth Patrick Lorton on 6 March 2024, trading 5,574 units of SDGR stock currently worth $24,191.

What does Schrodinger do?

Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

Complete history of David Equity stock trades at Schrodinger

Schrodinger executives and stock owners

Schrodinger executives and other stock owners filed with the SEC include:

• Dr. Ramy Farid Ph.D.,
  CEO, Pres & Director
• Yvonne Tran Esq.,
  Exec. VP, Chief Legal Officer & Sec.
• Dr. Karen Akinsanya Ph.D.,
  Exec. VP, Chief Biomedical Scientist and Head of Discovery R&D
• Ramy Farid,
  President, Chief Executive Officer, Director
• Cony D cruz,
  Executive Vice President - Chief Business Officer
• Yvonne Tran,
  Executive Vice President, Chief Legal Officer
• Dr. Richard A. Friesner,
  Co-Founder, Scientific Advisory Chairman and Director
• Richard Friesner,
  Independent Director
• Nancy Thornberry,
  Independent Director
• Gary Sender,
  Independent Director
• Rosana Kapeller-Libermann,
  Independent Director
• Timothy Wright,
  Independent Director
• Shane Brauner,
  Senior Vice President, Chief Information Officer
• Kenneth Lorton,
  Senior Vice President, Chief Technology Officer
• Karen Akinsanya,
  Executive Vice President, Chief Biomedical Scientist, Head of Discovery R&D
• Robert Abel,
  Executive Vice President - science
• Jorg Weiser,
  Executive Vice President, Managing Director
• Jennifer Daniel,
  Chief Human Resource Officer, Senior Vice President
• Joel Lebowitz,
  Executive Vice President, Chief Financial Officer
• Michael Lynton,
  Independent Chairman of the Board of Directors
• Michelle Byington,
  VP of HR
• Jennifer Mayer Daniel,
  Sr. VP & Chief HR Officer
• Jaren Irene Madden,
  Sr. VP of Investor Relations & Corp. Communications
• Shane Brauner,
  Exec. VP & Chief Information Officer
• Kenneth Patrick Lorton,
  Exec. VP & CTO
• Prof. William Goddard III,
  Co-Founder & Scientific Advisor
• Charles Ardai,
  10% owner
• Geoffrey Craig Porges,
  EVP & CFO
• David E Shaw,
  10% owner
• Gary L Ginsberg,
  Director
• Jeffrey Chodakewitz,
  Director
• & Melinda Gates Foundation ...,
  10% owner
• David E Schrodinger Equity ...,
  
• James E Deerfield Mgmt Iv, ...,
  
• Jenny Herman,
  SVP & Controller
• Arun Oberoi,
  Director
• Margaret Dugan,
  Chief Medical Officer